At the end of the latest market close, Concert Pharmaceuticals Inc. (CNCE) was valued at $8.30. In that particular session, Stock kicked-off at the price of $8.28 while reaching the peak value of $8.33 and lowest value recorded on the day was $8.27. The stock current value is $8.29.Recently in News on January 19, 2023, Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata. Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease. You can read further details here
Concert Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $8.34 on 01/20/23, with the lowest value was $5.82 for the same time period, recorded on 01/04/23.
Concert Pharmaceuticals Inc. (CNCE) full year performance was 166.88%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Concert Pharmaceuticals Inc. shares are logging -0.60% during the 52-week period from high price, and 222.57% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.57 and $8.34.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 899874 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Concert Pharmaceuticals Inc. (CNCE) recorded performance in the market was 42.12%, having the revenues showcasing 55.14% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 398.40M, as it employees total of 64 workers.
Market experts do have their say about Concert Pharmaceuticals Inc. (CNCE)
During the last month, 0 analysts gave the Concert Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.85, with a change in the price was noted +1.72. In a similar fashion, Concert Pharmaceuticals Inc. posted a movement of +26.06% for the period of last 100 days, recording 1,123,964 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CNCE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Concert Pharmaceuticals Inc. (CNCE)
Raw Stochastic average of Concert Pharmaceuticals Inc. in the period of last 50 days is set at 98.91%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 98.75%. In the last 20 days, the company’s Stochastic %K was 98.67% and its Stochastic %D was recorded 98.61%.
Bearing in mind the latest performance of Concert Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 42.12%. Additionally, trading for the stock in the period of the last six months notably improved by 87.36%, alongside a boost of 166.88% for the period of the last 12 months. The shares increased approximately by 12.16% in the 7-day charts and went down by 72.20% in the period of the last 30 days. Common stock shares were driven by 55.14% during last recorded quarter.